Ifabric Corp Stock Price, News & Analysis

iFabric (OTCQX:IFABF / TSX:IFA) announced on November 3, 2025 that its subsidiary Intelligent Fabric Technologies (North America) is launching its company‑owned apparel brand Verzus All Apparel at one of Canada’s leading wholesale club retailers.

The retailer introduced five men's Verzus All Apparel programs initially available online, featuring performance apparel using IFTNA’s textile technologies. The retailer has planned an expanded rollout for Spring 2026, indicating confidence in the brand’s market potential. Verzus All programs emphasize enhanced comfort, durability, and protection to showcase IFTNA’s proprietary technologies to a broader consumer market.

An example selection is accessible via the retailer’s online search for Verzus.

iFabric Corp (OTCQX:IFABF, TSX:IFA) announced on October 27, 2025 that it secured a new $2.5 million unsecured trade finance facility with Ebury Partners Canada Ltd. The facility is intended to provide additional working capital and support growth and expansion initiatives.

The company said it will also use Ebury's foreign exchange expertise and flexible risk management tools to better manage currency exposure. This unsecured facility will supplement iFabric's existing secured credit facility of up to $12.0 million with a Canadian chartered bank, which management expects will together support anticipated new revenues from recently announced programs.

iFabric (OTCQX:IFABF) announced that its subsidiary Intelligent Fabric Technologies (North America) Inc. has begun the launch of Doctor's Choice Next Generation scrubs with an initial rollout at a leading U.S. national big-box retailer. The first collections integrate IFTNA flagship technologies: PROTX2 (advanced antimicrobial), ecoPEL (C0 PFC-free DWR), and DryTX (moisture management).

Collections will launch online first, with in-store availability expected at the end of October 2025. Product claims include clinically proven antimicrobial finish, PFC-free water repellency, and wicking/quick-dry performance designed for clinical use.

iFabric Corp (OTCQX:IFABF) has announced that its subsidiary, Intelligent Fabric Technologies North America (IFTNA), has signed a significant licensing agreement with Mercury Athletics LLC to develop next-generation medical apparel under the Doctor's Choice® brand.

The collaboration will incorporate IFTNA's textile technologies, particularly PROTX2®, into healthcare scrubs and apparel. The partnership builds on Doctor's Choice's established reputation in diabetic and compression socks, expanding into the healthcare apparel sector. The new product line will be supported by IFTNA's peer-reviewed clinical trial published in the Journal of Hospital Infection in 2025.

iFabric Corp (OTCQX:IFABF) has renewed its license agreement with TUMI through its subsidiary Intelligent Fabric Technologies North America (IFTNA). The five-year extension continues the integration of IFTNA's PROTX2® antimicrobial technology across select TUMI products.

The renewed partnership will maintain PROTX2 implementation in TUMI's premium product lines, including the 19 Degree Polycarbonate carry-on linings, Travel Kits, Toiletry Kits, Laundry Bags, and select items within the Alpha Bravo, Alpha, Arrive' and McLaren collections.

iFabric Corp (OTCQX:IFABF) announced the expansion of its PROTX2 technology into the United Kingdom and European Union markets, marking a significant strategic expansion beyond North America. The company has secured a notable partnership with Marks & Spencer, which will incorporate PROTX2 technology into select items within its Autograph collections.

The PROTX2 brand mark will be prominently featured on merchandise hang tags both in-store and online, increasing brand visibility in these new regional markets. The company's Intelligent Fabric Technologies Division will support production programs incorporating PROTX2 technology in both the EU and UK regions.

iFabric Corp (OTCQX:IFABF) has announced the publication of groundbreaking clinical trial results in the Journal of Hospital Infection, demonstrating the effectiveness of their PROTX2® and ecoPEL™ antimicrobial technologies in healthcare settings.

The trial, conducted at MemorialCare Saddleback Medical Center, is the first successful antimicrobial textile trial to show statistically significant bacterial load reductions on scrubs in a real-world healthcare environment. The study validates that scrubs treated with PROTX2® and PROTX2® combined with ecoPEL™ significantly reduce surface bacterial contamination compared to untreated scrubs.

PROTX2® is EPA-registered and available for use throughout the United States, positioning IFTNA as a leader in healthcare-associated infection prevention solutions.

iFabric Corp (OTCQX:IFABF) reported its Q2 and H1 2025 financial results, with Q2 revenues remaining flat at $5.8 million compared to 2024. The company's H1 2025 revenues increased by 5% to $12.9 million. Q2 gross profit margin decreased to 37% from 42% in 2024, primarily due to $350,000 in brand advertising contributions.

The Intimate Apparel Division showed growth with a 10% revenue increase, while the Intelligent Fabrics Division saw a 7% decrease. The company reported a Q2 2025 net loss of $190,103 ($0.006 per share) compared to net earnings of $56,103 in 2024. Working capital remained strong at $19.2 million, with an unused $12 million credit facility available for future growth.

iFabric (OTCQX:IFABF) held its 2025 Annual General Meeting with approximately 65% shareholder participation, representing 19.5 million shares. All proposed matters received majority approval. The election of directors saw overwhelming support, with all six nominees receiving over 98.85% approval.

Shareholders also approved the appointment of BDO Canada LLP as auditors and fixed the number of directors at six. Notable directors Hylton Karon and Richard Macary received 99.86% and 99.94% of votes in favor, respectively.